The Journal of Organic Chemistry
Article
7.43−7.35 (m, 3H), 7.30−7.27 (m, 1H), 7.24−7.13 (m, 6H), 7.11 (d,
J = 0.9 Hz, 1H), 7.08−7.01 (m, 4H), 3.90 (p, J = 7.4 Hz, 1H), 3.46
(d, J = 7.4 Hz, 2H), 2.88 (d, J = 7.4 Hz, 2H), 2.24 (s, 3H). 13C NMR
(75 MHz, CDCl3) δ 189.2, 168.7, 148.9, 143.0, 139.1, 138.2, 134.8,
129.6, 129.4, 129.2, 129.1, 128.8, 128.6, 128.2, 127.0, 126.2, 125.8,
125.7, 119.6, 43.7, 42.0, 35.8, 20.9. IR (film): ν (cm−1) 3133, 3108,
3062, 3027, 2921, 2854, 1766, 1682, 1492, 1482, 1445, 1402, 1366,
1189, 1011, 915, 761, 737, 693, 511. HRMS (ESI, m/z) calcd for
C27H23BrN2O3Na [M + Na]+: 525.0784. Found: 525.0797.
MHz, CDCl3) δ 189.8, 163.0, 159.7, 143.6, 143.2, 138.2, 135.4,
135.40, 130.7, 130.6, 129.4, 128.8, 128.6, 128.3, 127.8, 126.9, 126.3,
125.6, 114.9, 114.6, 44.4, 43.1, 42.6. IR (film): ν (cm−1) 3138, 3108,
3063, 3029, 2923, 2855, 1682, 1598, 1507, 1493, 1445, 1403, 1304,
1218, 1156, 964, 913, 825, 757, 692, 538, 521, 488. HRMS (ESI, m/
z) calcd for C25H22FN2O [M + H]+: 385.1711. Found: 385.1721.
(R)-4-(2-Bromophenyl)-3-phenyl-1-(1-phenyl-1H-imidazol-2-yl)-
butan-1-one (3k). According to the general procedure, α,β-
unsaturated acyl imidazole 1b (27.4 mg, 0.10 mmol) reacted with
Hantzsch ester 2d (71.8 mg, 0.15 mmol) for 16 h, affording 3k as a
colorless oil (33.2 mg, 0.074 mmol, yield 74%) after column
chromatography purification (hex:AcOEt = 75:25). Enantiomeric
excess established by HPLC analysis using a Chiralcel OJ-H column,
ee = 90% (HPLC: OJ-H, 254 nm, n-hexane/isopropanol = 50:50, flow
rate 1.0 mL/min, 25 °C, tr (minor) = 11.3 min, tr (major) = 29.8
min). [α]D22 = −6.8° (c 1.0, CH2Cl2). 1H NMR (300 MHz, CDCl3) δ
7.49 (d, J = 8.0 Hz, 1H), 7.38−7.30 (m, 3H), 7.25−7.20 (m, 5H),
7.19−7.10 (m, 1H), 7.07 (d, J = 7.0 Hz, 2H), 6.99 (dd, J = 12.1, 5.0
Hz, 4H), 3.89−3.69 (m, 2H), 3.39−3.22 (m, 1H), 3.14−2.98 (m,
2H). 13C NMR (75 MHz, CDCl3) δ 189.8, 143.6, 143.3, 139.1, 138.2,
132.8, 131.5, 129.4, 128.8, 128.5, 128.2, 127.8, 127.8, 126.9, 126.8,
126.4, 125.6, 124.9, 44.0, 43.5, 41.3. IR (film): ν (cm−1) 3133, 3108,
3061, 3028, 2923, 2855, 1682, 1492, 1444, 1403, 1304, 1024, 964,
913, 753, 692, 659, 548, 519. HRMS (ESI, m/z) calcd for
C25H22BrN2O [M + H]+: 445.0910. Found: 445.0921.
(R)-3-Benzyl-1-(1-phenyl-1H-imidazol-2-yl)hexan-1-one (3g).
According to the general procedure, α,β-unsaturated acyl imidazole
1g (24.0 mg, 0.10 mmol) reacted with Hantzsch ester 2a (47.9 mg,
0.12 mmol) for 13 h, affording 3g as a colorless oil (19.2 mg, 0.058
mmol, yield 58%) after column chromatography purification
(hex:AcOEt = 80:20). Enantiomeric excess established by HPLC
analysis using a Chiralpak AD-H column, ee = 92% (HPLC: AD-H,
254 nm, n-hexane/isopropanol = 99:1, flow rate 1.0 mL/min, 25 °C,
1
tr (minor) = 13.5 min, tr (major) = 14.8 min). H NMR (300 MHz,
CDCl3) δ 7.47−7.42 (m, 3H), 7.25−7.19 (m, 5H), 7.17−7.12 (m,
4H), 3.18 (dd, J = 16.9, 6.7 Hz, 1H), 3.04 (dd, J = 16.9, 6.4 Hz, 1H),
2.67 (dd, J = 13.5, 6.9 Hz, 1H), 2.56 (dd, J = 13.5, 7.4 Hz, 1H), 2.47−
2.36 (m, 1H), 1.40−1.35 (m, 4H), 0.84 (t, J = 6.7 Hz, 3H). 13C NMR
(75 MHz, CDCl3) δ 191.2, 143.4, 140.8, 138.5, 129.4, 128.9, 128.7,
128.1, 126.9, 125.9, 125.8, 43.1, 40.7, 36.3, 35.7, 19.9, 14.2. All
analytical data are in accordance with the literature.6
(S)-3-Phenyl-1-(1-phenyl-1H-imidazol-2-yl)-4-(thiophen-2-yl)-
butan-1-one (3l). According to the general procedure, α,β-
unsaturated acyl imidazole 1b (27.4 mg, 0.10 mmol) reacted with
Hantzsch ester 2e (48.7 mg, 0.12 mmol) for 17 h, affording 3l as a
colorless oil (28.5 mg, 0.076 mmol, yield 76%) after column
chromatography purification (hex:AcOEt = 75:25). Enantiomeric
excess established by HPLC analysis using a Chiralcel OJ-H column,
ee = 92% (HPLC: OJ-H, 254 nm, n-hexane/isopropanol = 50:50, flow
rate 1.0 mL/min, 25 °C, tr (minor) = 20.4 min, tr (major) = 24.9
min). [α]D22 = −2.4° (c 1.0, CH2Cl2). 1H NMR (300 MHz, CDCl3) δ
7.44−7.32 (m, 3H), 7.28−7.13 (m, 6H), 7.10 (d, J = 1.0 Hz, 1H),
7.06−6.97 (m, 3H), 6.82 (dd, J = 5.1, 3.4 Hz, 1H), 6.69−6.62 (m,
1H), 3.73−3.57 (m, 2H), 3.52−3.36 (m, 1H), 3.27−3.06 (m, 2H).
13C NMR (75 MHz, CDCl3) δ 189.7, 143.5, 143.2, 142.2, 138.2,
(R)-3-Benzyl-4-methyl-1-(1-phenyl-1H-imidazol-2-yl)pentan-1-
one (3h). According to the general procedure, α,β-unsaturated acyl
imidazole 1h (24.0 mg, 0.10 mmol) reacted with Hantzsch ester 2a
(47.9 mg, 0.12 mmol) for 13 h, affording 3h as a colorless oil (17.7
mg, 0.053 mmol, yield 53%) after column chromatography
purification (hex:AcOEt = 80:20). Enantiomeric excess established
by HPLC analysis using a Chiralpak AD-H column, ee = 93%
(HPLC: AD-H, 254 nm, n-hexane/isopropanol = 98:2, flow rate 1.0
1
mL/min, 25 °C, tr (minor) = 8.4 min, tr (major) = 9.9 min). H
NMR (300 MHz, CDCl3) δ 7.45−7.40 (m, 3H), 7.25−7.11 (m, 9H),
3.17 (dd, J = 17.1, 5.9 Hz, 1H), 3.04 (dd, J = 17.1, 6.8 Hz, 1H), 2.69
(dd, J = 13.3, 6.4 Hz, 1H), 2.52−2.45 (m, 1H), 2.44−2.33 (m, 1H),
1.78−1.68 (m, 1H), 0.95 (d, J = 6.9 Hz, 3H), 0.91 (d, J = 6.9 Hz,
3H). 13C NMR (75 MHz, CDCl3) δ 191.2, 143.4, 141.1, 138.5, 129.3,
128.8, 128.6, 128.1, 126.9, 125.9, 125.7, 41.4, 39.6, 37.7, 29.6, 19.6,
18.5. All analytical data are in accordance with the literature.6
(R)-4-(4-Methoxyphenyl)-3-phenyl-1-(1-phenyl-1H-imidazol-2-
yl)butan-1-one (3i). According to the general procedure, α,β-
unsaturated acyl imidazole 1b (27.4 mg, 0.10 mmol) reacted with
Hantzsch ester 2b (51.5 mg, 0.12 mmol) for 16 h, affording 3i as a
pale yellow oil (39.6 mg, 0.10 mmol, yield quant.) after column
chromatography purification (hex:AcOEt = 75:25). Enantiomeric
excess established by HPLC analysis using a Chiralcel OJ-H column,
ee = 98% (HPLC: OJ-H, 254 nm, n-hexane/isopropanol = 50:50, flow
rate 1.0 mL/min, 25 °C, tr (minor) = 17.3 min, tr (major) = 45.5
min). 1H NMR (300 MHz, CDCl3) δ 7.40−7.33 (m, 3H), 7.25−7.12
(m, 6H), 7.09 (bs, 1H), 7.00−6.96 (m, 4H), 6.72 (d, J = 8.6 Hz, 2H),
3.74 (s, 3H), 3.67−3.54 (m, 2H), 3.45−3.34 (m, 1H), 2.88 (d, J = 7.0
Hz, 2H). 13C NMR (75 MHz, CDCl3) δ 190.0, 157.9, 144.1, 143.3,
138.2, 131.9, 130.2, 129.3, 128.8, 128.5, 128.2, 127.9, 126.8, 126.2,
125.6, 113.5, 55.1, 44.3, 43.2, 42.7. All analytical data are in
accordance with the literature.6
129.4, 128.9, 128.6, 128.3, 127.9, 126.8, 126.5, 126.5, 125.7, 123.5,
44.6, 43.3, 37.2. IR (film): ν (cm−1) 3132, 3107, 3062, 3028, 2916,
2849, 1682, 1597, 1492, 1444, 1403, 1305, 1034, 962, 914, 850, 757,
690, 518. HRMS (ESI, m/z) calcd for C23H21N2OS [M + H]+:
373.1369. Found: 373.1379.
(R)-4-(Benzyloxy)-3-phenyl-1-(1-phenyl-1H-imidazol-2-yl)butan-
1-one (3m). According to the general procedure, α,β-unsaturated acyl
imidazole 1b (27.4 mg, 0.10 mmol) reacted with Hantzsch ester 2f
(51.5 mg, 0.12 mmol) for 16 h, affording 3m as a colorless oil (14.3
mg, 0.036 mmol, yield 36%) after column chromatography
purification (hex:AcOEt = 80:20). Enantiomeric excess established
by HPLC analysis using a Chiralpak OD-H column, ee = 93%
(HPLC: OD-H, 254 nm, n-hexane/isopropanol = 95:5, flow rate 1.0
1
mL/min, 25 °C, tr (minor) = 20.4 min, tr (major) = 23.1 min). H
NMR (300 MHz, CDCl3) δ 7.43−7.32 (m, 3H), 7.32−7.17 (m,
11H), 7.12 (d, J = 0.9 Hz, 1H), 7.04−6.97 (m, 2H), 4.45 (s, 2H),
3.85−3.57 (m, 4H), 3.52−3.38 (m, 1H). 13C NMR (75 MHz,
CDCl3) δ 189.8, 143.3, 141.9, 138.3, 129.4, 128.8, 128.5, 128.4, 128.2,
128.0, 127.6, 127.4, 126.8, 126.6, 125.7, 74.9, 73.0, 42.3, 41.7. All
analytical data are in accordance with the literature.6
(R)-4-(4-Fluorophenyl)-3-phenyl-1-(1-phenyl-1H-imidazol-2-yl)-
butan-1-one (3j). According to the general procedure, α,β-
unsaturated acyl imidazole 1b (27.4 mg, 0.10 mmol) reacted with
Hantzsch ester 2c (50.1 mg, 0.12 mmol) for 18 h, affording 3j as a
pale yellow oil (35.5 mg, 0.092 mmol, yield 92%) after column
chromatography purification (hex:AcOEt = 75:25). Enantiomeric
excess established by HPLC analysis using a Chiralcel OJ-H column,
ee = 88% (HPLC: OJ-H, 254 nm, n-hexane/isopropanol = 50:50, flow
rate 1.0 mL/min, 25 °C, tr (minor) = 12.3 min, tr (major) = 22.9
min). [α]D22 = −5.8° (c 1.0, CH2Cl2). 1H NMR (300 MHz, CDCl3) δ
7.41−7.34 (m, 3H), 7.24−7.20 (m, 3H), 7.17−7.13 (m, 3H), 7.10 (d,
J = 0.9 Hz, 1H), 7.04−6.96 (m, 4H), 6.88−6.82 (m, 2H), 3.65−3.54
(m, 2H), 3.49−3.38 (m, 1H), 2.97−2.84 (m, 2H). 13C NMR (75
(R)-tert-Butyl (4-oxo-2-phenyl-4-(1-phenyl-1H-imidazol-2-yl)-
butyl)carbamate (3n). According to the general procedure, α,β-
unsaturated acyl imidazole 1b (27.4 mg, 0.10 mmol) reacted with
Hantzsch ester 2g (52.6 mg, 0.12 mmol) for 18 h, affording 3n as a
pale yellow oil (38.5 mg, 0.095 mmol, yield 95%) after column
chromatography purification (hex:AcOEt = 60:40). Enantiomeric
excess established by HPLC analysis using a Chiralpak OD-H column,
ee = 93% (HPLC: OD-H, 254 nm, n-hexane/isopropanol = 95:5, flow
rate 1.0 mL/min, 25 °C, tr (minor) = 23.4 min, tr (major) = 27.1
min). [α]D22 = −11.6° (c 1.0, CH2Cl2). 1H NMR (300 MHz, CDCl3)
δ 7.44−7.37 (m, 3H), 7.30−7.26 (m, 2H), 7.25−7.18 (m, 4H), 7.14−
H
J. Org. Chem. XXXX, XXX, XXX−XXX